Literature DB >> 31781716

A primary aldosteronism-like phenotype identified with the aldosterone-to-angiotensin II ratio in black men: the SABPA study.

Johannes M van Rooyen1, Marko Poglitsch2, Hugo W Huisman3, Lebo F Gafane-Matemane3, Yolandi Breet4, Leonè Malan3.   

Abstract

INTRODUCTION: Black populations may be more likely to have primary aldosteronism (PA) due to adrenal hyperplasia or other forms of adrenal hyperactivity, with suppressed renin levels and high levels of aldosterone, which may contribute to the development of hypertension.
METHODS: This sub-study involved 35 black men matched for age, gender and race, and aged 20-65 years, living in the North West Province of South Africa. RAAS triple-A analysis was carried out with LC-MS/MS quantification. Blood pressure, electrocardiography and other variables were determined with known methods.
RESULTS: Hypertensive subjects with higher aldosterone levels showed an increased aldosterone-angiotensin II ratio (AA2 ratio) compared to the hypertensive subjects with low aldosterone levels (10.2 vs 3.0 pmol/l; p = 0.003). The serum potassium concentration was significantly lower in the high-aldosterone group and the serum sodium-potassium ratio was significantly higher compared to the low-aldosterone group (3.9 vs 4.5, p = 0.016, 34.8 vs 31.8, p = 0.032, respectively). Furthermore, aldosterone was positively associated with both left ventricular hypertrophy (Cornell product) (Spearman R = 0.560; p = 0.037) and kidney function [albumin-to-creatinine ratio (ACR) ] (Spearman R = 0.589, p = 0.021) in the hypertensive high-serum aldosterone group.
CONCLUSIONS: The AA2 ratio, a novel screening test that is currently being validated for PA case detection, was used to identify a PA-like phenotype in black men. Excess aldosterone was associated with endothelial dysfunction and left ventricular hypertrophy, independent of blood pressure.

Entities:  

Keywords:  RAAS; aldosterone; blacks; hypertension; organ damage

Mesh:

Substances:

Year:  2019        PMID: 31781716      PMCID: PMC8762789          DOI: 10.5830/CVJA-2019-059

Source DB:  PubMed          Journal:  Cardiovasc J Afr        ISSN: 1015-9657            Impact factor:   1.167


  24 in total

Review 1.  Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction--the Hoorn Study.

Authors:  Coen D A Stehouwer; Ronald M A Henry; Jacqueline M Dekker; Giel Nijpels; Robert J Heine; Lex M Bouter
Journal:  Kidney Int Suppl       Date:  2004-11       Impact factor: 10.545

Review 2.  Is Primary Aldosteronism Still Largely Unrecognized?

Authors:  Fabrizio Buffolo; Silvia Monticone; Jacopo Burrello; Martina Tetti; Franco Veglio; Tracy Ann Williams; Paolo Mulatero
Journal:  Horm Metab Res       Date:  2017-11-16       Impact factor: 2.936

Review 3.  Recent advances in understanding hypertension development in sub-Saharan Africa.

Authors:  A E Schutte; S Botha; C M T Fourie; L F Gafane-Matemane; R Kruger; L Lammertyn; L Malan; C M C Mels; R Schutte; W Smith; J M van Rooyen; L J Ware; H W Huisman
Journal:  J Hum Hypertens       Date:  2017-03-23       Impact factor: 3.012

4.  Physiological Phenotyping for Personalized Therapy of Uncontrolled Hypertension in Africa.

Authors:  Adeseye Akintunde; Justus Nondi; Kennedy Gogo; Erika S W Jones; Brian L Rayner; Daniel G Hackam; J David Spence
Journal:  Am J Hypertens       Date:  2017-09-01       Impact factor: 2.689

5.  High Frequency of Variants of Candidate Genes in Black Africans with Low Renin-Resistant Hypertension.

Authors:  Erika S Jones; J D Spence; Adam D Mcintyre; Justus Nondi; Kennedy Gogo; Adeseye Akintunde; Daniel G Hackam; Brian L Rayner
Journal:  Am J Hypertens       Date:  2017-05-01       Impact factor: 2.689

6.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

Authors:  John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2016-03-02       Impact factor: 5.958

7.  Chronic depression symptoms desensitize renin activity to protect against volume-loading hypertension in Blacks: The SABPA study.

Authors:  Arnoldeen C De Vos; Leone Malan; Yackoob K Seedat; Marike Cockeran; Nicolaas T Malan
Journal:  Physiol Behav       Date:  2018-06-28

8.  Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry.

Authors:  E Born-Frontsberg; M Reincke; L C Rump; S Hahner; S Diederich; R Lorenz; B Allolio; J Seufert; C Schirpenbach; F Beuschlein; M Bidlingmaier; S Endres; M Quinkler
Journal:  J Clin Endocrinol Metab       Date:  2009-02-03       Impact factor: 5.958

9.  Cohort Profile: Sympathetic activity and Ambulatory Blood Pressure in Africans (SABPA) prospective cohort study.

Authors:  Leoné Malan; Mark Hamer; Nancy Frasure-Smith; Hendrik S Steyn; Nicolaas T Malan
Journal:  Int J Epidemiol       Date:  2014-10-24       Impact factor: 7.196

10.  Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants.

Authors: 
Journal:  Lancet       Date:  2016-11-16       Impact factor: 79.321

View more
  2 in total

1.  Poor Performance of Angiotensin II Enzyme-Linked Immuno-Sorbent Assays in Mostly Hypertensive Cohort Routinely Screened for Primary Aldosteronism.

Authors:  Agnieszka Łebek-Szatańska; Lucyna Papierska; Piotr Glinicki; Wojciech Zgliczyński
Journal:  Diagnostics (Basel)       Date:  2022-04-30

2.  Associations of central and peripheral blood pressure with the renin-angiotensin-aldosterone system in healthy young adults: the African-PREDICT study.

Authors:  Lebo F Gafane-Matemane; Nametsegang L Mokae; Yolandi Breet; Marko Poglitsch; Aletta E Schutte
Journal:  Hypertens Res       Date:  2020-10-30       Impact factor: 3.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.